PD-1/PD-L1
Gli inibitori di PD-1/PD-L1 sono inibitori del checkpoint immunitario che bloccano l'interazione tra la proteina di morte cellulare programmata 1 (PD-1) sui linfociti T e il suo ligando PD-L1 sulle cellule tumorali. Questa interazione sopprime normalmente la risposta immunitaria e permette alle cellule tumorali di sfuggire al riconoscimento immunitario. Inibendo PD-1/PD-L1, questi inibitori potenziano la capacità del sistema immunitario di riconoscere e distruggere le cellule tumorali, inducendo apoptosi e regressione tumorale. Gli inibitori di PD-1/PD-L1 sono fondamentali nella ricerca sull'immunoterapia e nel trattamento del cancro. Presso CymitQuimica, offriamo una gamma di inibitori di PD-1/PD-L1 di alta qualità per supportare la tua ricerca in immuno-oncologia, apoptosi e terapia del cancro.
Trovati 147 prodotti per "PD-1/PD-L1".
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purezza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:145.14 kDaSintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Purezza:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:143.78 kDaZimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purezza:95%Colore e forma:Transparent LiquidPeso molecolare:146.54 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purezza:95.07% - 99.29%Colore e forma:White SolidPeso molecolare:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purezza:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:146.03 kDaBMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purezza:97.36%Colore e forma:SolidPeso molecolare:631.11Ref: TM-T10565
1mg52,00€5mg120,00€1mL*10mM (DMSO)169,00€10mg187,00€25mg380,00€50mg612,00€100mg973,00€200mg1.305,00€Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Purezza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:145.72 kDaDostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purezza:>95%Colore e forma:Transparent LiquidPeso molecolare:144.18 kDaTislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purezza:95.07%Colore e forma:Transparent LiquidPeso molecolare:145 kDaEzabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purezza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:145.21 kDaSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purezza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Colore e forma:Transparent LiquidPeso molecolare:145.74 kDaPidilizumab
CAS:Pidilizumab is a humanized mAb targeting PD-1 and DLL1 that inhibits tumor growth by boosting T cell and NK cell activity.Purezza:98%Colore e forma:LiquidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurezza:98%Colore e forma:SolidTobemstomig
CAS:Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T cell activation. By blocking these immune checkpoints, it can promote cytotoxic T cell responses and exhibits potential antitumor activity. [Molecular weight 145.24 kDa.]Rilvegostomig
CAS:Rilvegostomig is a bispecific humanized IgG1 antibody targeting the immune-regulating receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T cell activation, fostering a robust anti-tumor immune response, especially in cancers such as non-small cell lung cancer (NSCLC). Molecular weight: 146.06 KD.Colore e forma:LiquidGarivulimab
CAS:Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.Purezza:95%Colore e forma:Transparent LiquidAcrixolimab
CAS:Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].Purezza:98%Colore e forma:LiquidPD-1/PD-L1-IN-49
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.Formula:C27H32N4O5Colore e forma:SolidPeso molecolare:492.567Opamtistomig
CAS:Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.Colore e forma:LiquidDanburstotug
CAS:Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).Purezza:98%Colore e forma:Liquid
